Citizens reiterates Lazard stock rating citing strong forward indicators

Citizens maintained its Market Outperform rating and $60.00 price target on Lazard (NYSE:LAZ) after its Q3 2026 results. Lazard reported adjusted EPS of $0.36, below estimates, and revenue of $805M, up 11% YoY but below expectations. Shares have fallen 21% YTD. Goldman Sachs raised its price target to $35 but kept a Sell rating, citing expense management. Lazard's dividend yield is 5.36%.

Original reporting
Published Oct 23, 2026, 9:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 9:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LAZ
Bearish
high confidence
Mentioned
$LAZ
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LAZBearishMed
01

Why it matters

The earnings miss may trigger short-term selling, but the stable rating and dividend yield could support the stock.

02

Market read

First disclosure of Lazard's Q3 2026 earnings miss, providing fresh data for traders to assess short-term price impact.

03

What to watch

Fourth-quarter fee timing could improve results, and the 5.36% dividend yield may attract income-focused investors.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Lazard (NYSE:LAZ) is a global financial advisory and asset management firm. The article reports its Q3 2026 earnings and analysts' reactions.

Company-level read

Ticker impact

$LAZBearishHigh confidence
Context

Citizens maintained its Outperform rating and $60 price target after Lazard reported Q3 2026 earnings that missed estimates.

Expected impact

downward pressure as the market prices in the earnings miss and revenue shortfall

Evidence & confidence

The miss on EPS ($0.36 vs $0.45 est) and revenue ($805M vs $869M est) are material and were first disclosed in this article.

Market effects

Potential drag on the financial advisory and asset management sector as peers may face similar earnings pressures.

Limited to U.S. markets; no broader regional effect noted.

Modest, primarily affecting investors tracking mid-cap advisory firms.

Counterpoint

Citizens' continued Outperform rating suggests belief in a rebound, offering a possible buying opportunity on dip.

Key entities

  • Citizens

    Maintained Market Outperform rating and $60 price target for Lazard.

  • Goldman Sachs

    Raised price target to $35 from $32 despite a Sell rating.

Related articles

$LAZLow

Lazard Reports October 2026 Assets Under Management

Lazard (NYSE: LAZ) reported $282.4B in AUM for October 2026, down from $284B in September. The decline included market depreciation of $1.9B, FX depreciation of $1.4B, and net inflows of $1.7B. Lazard is a financial advisory and asset management firm listed on the NYSE.

$LAZHighAI 8/10

Lazard completes Campbell Lutyens acquisition, launches new unit

Lazard Inc. (NYSE:LAZ) completed its acquisition of Campbell Lutyens, launching Lazard CL, a private capital advisory unit. The deal, paid mostly in Lazard stock, combines their advisory operations. Lazard CL has 300+ professionals across 19 offices and has advised on over $1 trillion in capital. The company expects Lazard CL to generate $500M in revenue in 2027, boosting earnings.

$LAZMedAI 8/10

Lazard Completes Its Acquisition of Campbell Lutyens and Launches Lazard CL, the Global Leader for the Next Era of Private Capital

Lazard Inc. (NYSE: LAZ) completed its acquisition of Campbell Lutyens, launching Lazard CL, a global leader in private capital advisory. The deal, announced in April 2026, combines Lazard's and Campbell Lutyens' operations, creating a platform with 300 professionals and 19 offices worldwide. Lazard CL is expected to generate $500 million in revenue in 2027 and be accretive to earnings, according to the company.